Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 5/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | PNMT | P11086 | 6/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23652645 | 0.94 | DRD2 (0.45) | DRD2DRD3CYP11B2DRD4CA1 | |
| SCHEMBL2731329 | 0.81 | CA1 (0.48) | DRD2DRD3CA1CA2ACHE | |
| SCHEMBL1743661 | 0.81 | CA1 (0.48) | DRD2DRD3CA1CA2ACHE | |
| SCHEMBL2730699 | 0.81 | CA1 (0.48) | DRD2DRD3CA1CA2ACHE | |
| SCHEMBL14525540 | 0.79 | DRD2 (0.49) | DRD2DRD3CYP11B2PNMT | |
| SCHEMBL1337530 | 0.77 | DRD2 (0.60) | DRD2CA1CA2ACHEMTNR1A | |
| SCHEMBL20909682 | 0.77 | DRD2 (0.46) | DRD2DRD3DRD4CA1CA2 | |
| SCHEMBL23552324 | 0.76 | MCHR1 (0.41) | DRD2DRD3CYP11B2CA1CA2 | |
| SCHEMBL2724775 | 0.76 | OPRK1 (0.57) | DRD2DRD3 | |
| SCHEMBL2722643 | 0.76 | OPRK1 (0.57) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008001160-A1 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-7304065-B2 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | HU XIUFENG E | 2006-11-02 | — | — | US | disclosed |
| EP-1667958-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005033063-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050075324-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075324-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | DRD2 96/4885DRD3 102/4885CYP11B2 136/4885 |
| US-20060247239-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | DRD2 96/4885DRD3 102/4885CYP11B2 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.